Found: 213
Select item for more details and to access through your institution.
NPM1 is overexpressed in hyperdiploid multiple myeloma due to a gain of chromosome 5 but is not delocalized to the cytoplasm.
- Published in:
- Genes, Chromosomes & Cancer, 2010, v. 49, n. 4, p. 333, doi. 10.1002/gcc.20745
- By:
- Publication type:
- Article
Enrichment of B cell receptor signaling and epidermal growth factor receptor pathways in monoclonal gammopathy of undetermined significance: a genome-wide genetic interaction study.
- Published in:
- Molecular Medicine, 2018, v. 24, n. 1, p. N.PAG, doi. 10.1186/s10020-018-0031-8
- By:
- Publication type:
- Article
Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Prognostic significance of increased bone marrow microcirculation in newly diagnosed multiple myeloma: results of a prospective DCE-MRI study.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Daratumumab, lenalidomide, and dexamethasone in systemic light‐chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 7, p. E253, doi. 10.1002/ajh.26191
- By:
- Publication type:
- Article
Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 11, p. E473, doi. 10.1002/ajh.24533
- By:
- Publication type:
- Article
No regression of renal AL amyloid in monoclonal gammopathy after successful autologous blood stem cell transplantation and significant clinical improvement.
- Published in:
- Nephrology Dialysis Transplantation, 2003, v. 18, n. 12, p. 2644, doi. 10.1093/ndt/gfg436
- By:
- Publication type:
- Article
Multiple myeloma and renal failure.
- Published in:
- Nephrology Dialysis Transplantation, 2000, v. 15, n. 3, p. 301, doi. 10.1093/ndt/15.3.301
- By:
- Publication type:
- Article
Therapiestrategien beim Multiplen Myelom: die künftige Rolle von Bendamustin.
- Published in:
- Oncology Research & Treatment, 2013, v. 36, p. 19, doi. 10.1159/000346107
- By:
- Publication type:
- Article
Investigation of Rare Non-Coding Variants in Familial Multiple Myeloma.
- Published in:
- Cells (2073-4409), 2023, v. 12, n. 1, p. 96, doi. 10.3390/cells12010096
- By:
- Publication type:
- Article
Bone marrow microcirculation analysis in multiple myeloma by contrast-enhanced dynamic magnetic resonance imaging.
- Published in:
- International Journal of Cancer, 2001, v. 93, n. 6, p. 862, doi. 10.1002/ijc.1421
- By:
- Publication type:
- Article
Author Correction: Functional dissection of inherited non-coding variation influencing multiple myeloma risk.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma.
- Published in:
- Cytometry. Part B, 2018, v. 94, n. 5, p. 611, doi. 10.1002/cyto.b.21636
- By:
- Publication type:
- Article
Potential therapeutic targets in plasma cell disorders: A flow cytometry study.
- Published in:
- Cytometry. Part B, 2017, v. 92, n. 2, p. 145, doi. 10.1002/cyto.b.21351
- By:
- Publication type:
- Article
A precision‐based exercise program for patients with multiple myeloma.
- Published in:
- European Journal of Haematology, 2023, v. 111, n. 6, p. 930, doi. 10.1111/ejh.14106
- By:
- Publication type:
- Article
First‐line therapy with bendamustine/prednisone/bortezomib—A GMMG trial for non‐transplant eligible symptomatic multiple myeloma patients.
- Published in:
- European Journal of Haematology, 2020, v. 105, n. 2, p. 116, doi. 10.1111/ejh.13409
- By:
- Publication type:
- Article
Quality of life is maintained with ixazomib maintenance in post‐transplant newly diagnosed multiple myeloma: The TOURMALINE‐MM3 trial.
- Published in:
- European Journal of Haematology, 2020, v. 104, n. 5, p. 443, doi. 10.1111/ejh.13379
- By:
- Publication type:
- Article
Genomewide association study on monoclonal gammopathy of unknown significance (MGUS).
- Published in:
- European Journal of Haematology, 2017, v. 99, n. 1, p. 70, doi. 10.1111/ejh.12892
- By:
- Publication type:
- Article
Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells.
- Published in:
- BMC Medical Genomics, 2015, v. 8, p. 1, doi. 10.1186/s12920-015-0161-6
- By:
- Publication type:
- Article
Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials.
- Published in:
- BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-11507-9
- By:
- Publication type:
- Article
Comparison of IGLV2‐14 light chain sequences of patients with AL amyloidosis or multiple myeloma.
- Published in:
- FEBS Journal, 2023, v. 290, n. 17, p. 4256, doi. 10.1111/febs.16805
- By:
- Publication type:
- Article
Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma.
- Published in:
- Journal of Clinical Apheresis, 2014, v. 29, n. 6, p. 299, doi. 10.1002/jca.21323
- By:
- Publication type:
- Article
Multiples Myelom – bald heilbar?
- Published in:
- Der Internist, 2021, v. 62, n. 5, p. 562, doi. 10.1007/s00108-021-01010-3
- By:
- Publication type:
- Article
Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma.
- Published in:
- Molecules, 2020, v. 25, n. 1, p. 134, doi. 10.3390/molecules25010134
- By:
- Publication type:
- Article
Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression.
- Published in:
- Nature Communications, 2016, v. 7, n. 11, p. 13656, doi. 10.1038/ncomms13656
- By:
- Publication type:
- Article
Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma.
- Published in:
- Nature Communications, 2016, v. 7, n. 1, p. 10290, doi. 10.1038/ncomms10290
- By:
- Publication type:
- Article
Kyphoplasty in patients with multiple myeloma a retrospective comparative pilot study.
- Published in:
- Journal of Surgical Oncology, 2012, v. 105, n. 7, p. 679, doi. 10.1002/jso.22101
- By:
- Publication type:
- Article
Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics.
- Published in:
- Genes, Chromosomes & Cancer, 2005, v. 44, n. 2, p. 194, doi. 10.1002/gcc.20231
- By:
- Publication type:
- Article
Duplication of chromosome arms 9q and 11q: Evidence for a novel, 14q32 translocationindependent pathogenetic pathway in multiple myeloma.
- Published in:
- Genes, Chromosomes & Cancer, 2005, v. 42, n. 1, p. 78, doi. 10.1002/gcc.20098
- By:
- Publication type:
- Article
Teclistamab zur Therapie beim multiplen Myelom.
- Published in:
- Innere Medizin (2731-7080), 2023, v. 64, n. 2, p. 214, doi. 10.1007/s00108-022-01438-1
- By:
- Publication type:
- Article
Genome-wide interaction and pathway-based identification of key regulators in multiple myeloma.
- Published in:
- Communications Biology, 2019, v. 2, n. 1, p. N.PAG, doi. 10.1038/s42003-019-0329-2
- By:
- Publication type:
- Article
Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells.
- Published in:
- Oncogene, 2005, v. 24, n. 21, p. 3512, doi. 10.1038/sj.onc.1208536
- By:
- Publication type:
- Article
Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 5, p. 385, doi. 10.1016/j.clml.2023.02.006
- By:
- Publication type:
- Article
P-188: Carfilzomib, lenalidomide, and dexamethasone followed by salvage autologous stem cell transplant with or without maintenance for relapsed or refractory multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S140, doi. 10.1016/S2152-2650(21)02315-6
- By:
- Publication type:
- Article
P-177: Predictive factors for severe infections and early death during novel agent-based induction therapy in newly diagnosed, transplant-eligible myeloma: a multicohort analysis from phase III trials.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S133, doi. 10.1016/S2152-2650(21)02304-1
- By:
- Publication type:
- Article
P-138: Frequent magnetic resonance imaging partially reduces the development of end organ damage in patients with smoldering myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S110, doi. 10.1016/S2152-2650(21)02265-5
- By:
- Publication type:
- Article
P-060: Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single cell transcriptomics.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S71, doi. 10.1016/S2152-2650(21)02194-7
- By:
- Publication type:
- Article
P-049: The spatial sub-clonal architecture in newly diagnosed myeloma patients revealed by whole genome and single-cell sequencing.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S65, doi. 10.1016/S2152-2650(21)02183-2
- By:
- Publication type:
- Article
P-052: Identification of novel genetic loci for risk of multiple myeloma by functional annotation.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S66, doi. 10.1016/S2152-2650(21)02186-8
- By:
- Publication type:
- Article
P-018: Automatic analysis of magnetic resonance imaging in multiple myeloma patients: deep-learning based pelvic bone marrow segmentation and radiomics analysis for prediction of plasma cell infiltration.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S49, doi. 10.1016/S2152-2650(21)02152-2
- By:
- Publication type:
- Article
P-017: Repeatability and reproducibility of apparent diffusion coefficient measurements of bone marrow in magnetic resonance imaging of multiple myeloma patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S48, doi. 10.1016/S2152-2650(21)02151-0
- By:
- Publication type:
- Article
P-012: Automatic bone marrow segmentation in whole-body magnetic resonance imaging: towards comprehensive, objective MRI-phenotypic bone marrow characterization in multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S45, doi. 10.1016/S2152-2650(21)02146-7
- By:
- Publication type:
- Article
OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S17, doi. 10.1016/S2152-2650(21)02101-7
- By:
- Publication type:
- Article
OAB-023: Efficacy and safety of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with progressive multiple myeloma after 1–3 prior lines of therapy: Initial results from CARTITUDE-2.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S15, doi. 10.1016/S2152-2650(21)02097-8
- By:
- Publication type:
- Article
OAB-007: Single-cell multiomic analysis identifies regulatory programs in relapsed/refractory multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S5, doi. 10.1016/S2152-2650(21)02081-4
- By:
- Publication type:
- Article
OAB-001: Overall survival and progression-free survival by treatment duration with Daratumumab + Lenalidomide/Dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3 MAIA study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S1, doi. 10.1016/S2152-2650(21)02075-9
- By:
- Publication type:
- Article
MM-155: Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S424, doi. 10.1016/S2152-2650(21)01950-9
- By:
- Publication type:
- Article
Poster: MM-155: Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S252, doi. 10.1016/S2152-2650(21)01581-0
- By:
- Publication type:
- Article
Comparison of Granulocyte colony stimulating factor support versus antibiotic prophylaxis in autologous stem cell transplantation in multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e292, doi. 10.1016/j.clml.2019.09.480
- By:
- Publication type:
- Article
Health-related quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: the TOURMALINE-MM3 trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e290, doi. 10.1016/j.clml.2019.09.477
- By:
- Publication type:
- Article